Update in management of ganciclovir-resistant cytomegalovirus infection
Author:
- 1 August 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 21 (4) , 433-437
Abstract
The present review summarizes recent developments in pathogenesis, prevention, and management of ganciclovir-resistant cytomegalovirus infection. Basic science advances include reports of new resistance mutations and multidrug resistance. Innovative studies of the host immune response have shed light on differential risk. New laboratory techniques include rapid assays for resistance and measurement of ganciclovir levels. Clinical developments include studies on ganciclovir-resistant cytomegalovirus infection in thoracic transplant recipients and aspects of cytomegalovirus infection prevention. Although no resistance was seen in the valganciclovir arm of a prophylaxis trial, resistance has been described after both prophylactic and preemptive valganciclovir therapy. In the HIV realm, the incidence of ganciclovir-resistant cytomegalovirus infection has fallen dramatically. Newer options for therapy include maribavir, leflunomide, high-dose ganciclovir, switching to a sirolimus-based regimen, and the antimalarial drug, artesunate. Antiviral-resistant cytomegalovirus infection remains a feared complication of transplantation but is less frequently seen in AIDS patients in the current era. New research on resistance mutations and pathogenesis has enhanced clinical understanding of risk. Although preemptive strategies and valganciclovir prophylaxis are associated with less resistance than oral ganciclovir, resistant cytomegalovirus infection has not been eliminated. Several strategies and newer drugs hold promise for the future.Keywords
This publication has 43 references indexed in Scilit:
- Development of SYBR Green I-based real-time PCR assay for detection of drug resistance mutations in cytomegalovirusJournal of Virological Methods, 2008
- Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantJournal of Virology, 2008
- Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical SpecimensAntimicrobial Agents and Chemotherapy, 2007
- Resistance to Combined Ganciclovir and Foscarnet Therapy in a Liver Transplant Recipient with Possible Dual-Strain Cytomegalovirus CoinfectionLiver Transplantation, 2007
- Rapid Detection Directly from Patient Serum Samples of Human Cytomegalovirus UL97 Mutations Conferring Ganciclovir ResistanceJournal of Clinical Microbiology, 2007
- Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir ResistanceThe Journal of Infectious Diseases, 2007
- Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipientsJournal of Clinical Virology, 2007
- Multidrug Resistance Conferred by Novel DNA Polymerase Mutations in Human Cytomegalovirus IsolatesAntimicrobial Agents and Chemotherapy, 2007
- Absence of Cytomegalovirus‐Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid‐Organ Transplant RecipientsThe Journal of Infectious Diseases, 2004
- Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplantsThe Lancet, 2000